Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of ...
Rationale and design of phase 1 FTIH study of FOXP3 antisense oligonucleotide AZD8701 in patients with selected advanced solid tumors. This is an ASCO Meeting Abstract from the 2022 ASCO Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results